R R

What Is Ohtuvayre?

Ohtuvayre is a prescription inhaled medication containing ensifentrine, a dual phosphodiesterase 3 and phosphodiesterase 4 inhibitor. It is approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. Ohtuvayre is administered through a nebulizer twice daily to help manage ongoing breathing symptoms. It is not a rescue medication for sudden shortness of breath or acute bronchospasm. Patients should continue their prescribed rescue treatment for unexpected breathing emergencies.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Ohtuvayre?

Ohtuvayre is a prescription inhaled medication containing ensifentrine, a dual phosphodiesterase 3 and phosphodiesterase 4 inhibitor. It is approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. Ohtuvayre is administered through a nebulizer twice daily to help manage ongoing breathing symptoms. It is not a rescue medication for sudden shortness of breath or acute bronchospasm. Patients should continue their prescribed rescue treatment for unexpected breathing emergencies.

read more about ohtuvayre ...

Copy this HTML:

Copy HTML Copied!

How Does Ohtuvayre Work?

Ohtuvayre inhibits phosphodiesterase 3 and phosphodiesterase 4 enzymes, which break down cyclic adenosine monophosphate in cells. Inhibiting these enzymes increases intracellular signaling involved in relaxing airway smooth muscle and regulating inflammatory activity. Its combined effects contribute to improved airflow in patients with COPD. Ohtuvayre works through a different mechanism from beta-agonist bronchodilators and anticholinergic inhalers. It is intended for ongoing maintenance treatment rather than rapid reversal of an acute breathing episode.

Who Can Receive Ohtuvayre Treatment?

Ohtuvayre is approved for adults with chronic obstructive pulmonary disease, a long-term lung condition that can cause persistent airflow limitation, coughing, mucus production, and breathlessness. A healthcare professional considers symptoms, lung function, existing inhaled medications, and other medical conditions before prescribing it. Ohtuvayre can be incorporated into an individualized maintenance regimen. Its safety and effectiveness have not been established in children, and it is not approved to treat asthma or sudden COPD attacks.

How Is Ohtuvayre Administered?

The recommended dose of Ohtuvayre is 3 mg, contained in one 2.5 mL single-dose ampule, inhaled twice daily using a standard jet nebulizer with a mouthpiece. Treatments are generally given once in the morning and once in the evening. The ampule should be shaken according to its instructions before the contents are placed into the nebulizer cup. Do not mix Ohtuvayre with other nebulized medications because compatibility has not been established. The solution should not be swallowed or injected.

What Are the Side Effects and Warnings of Ohtuvayre?

Common adverse effects include back pain, increased blood pressure, urinary tract infections, and diarrhea. Serious concerns include paradoxical bronchospasm, which can cause breathing to worsen immediately after inhalation. Psychiatric adverse reactions, including depression and suicidal thoughts or behavior, have also been reported. Patients with a history of depression or other psychiatric conditions require careful assessment. Ohtuvayre should not be used in patients with known hypersensitivity to ensifentrine or other product ingredients. Sudden breathing deterioration requires prompt medical attention.

Common Questions About Ohtuvayre

Is Ohtuvayre a rescue inhaler?

No. Ohtuvayre is a twice-daily maintenance treatment for COPD and is not intended to relieve sudden breathing problems.

Does Ohtuvayre contain a steroid?

No. Ohtuvayre contains ensifentrine, a dual PDE3 and PDE4 inhibitor. It is not a corticosteroid.

How often is Ohtuvayre used?

Ohtuvayre is administered twice daily, generally once in the morning and once in the evening, using a standard jet nebulizer with a mouthpiece.

Can Ohtuvayre cause breathing problems?

Yes. Ohtuvayre can cause paradoxical bronchospasm, in which breathing worsens unexpectedly after treatment. Stop the medication and seek medical assistance if this occurs.

References

DailyMed - OHTUVAYRE (ensifentrine) inhalation suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6433c98-41a0-4f99-8f7f-d0e9db6e3f40. Date Accessed October 22, 2026.

Drug Trials Snapshots: OHTUVAYRE. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ohtuvayre. Date Accessed October 22, 2026.

Ensifentrine. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Ensifentrine. Date Accessed October 22, 2026.

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials). American Journal of Respiratory and Critical Care Medicine. https://pubmed.ncbi.nlm.nih.gov/37364283/. Date Accessed October 22, 2026.

Ensifentrine Oral Inhalation. MedlinePlus. https://medlineplus.gov/druginfo/meds/a624040.html. Date Accessed October 22, 2026.